美罗华联合含吡柔比星化疗方案治疗非霍奇金淋巴瘤的疗效及对相关标志物水平的影响  

Efficacy of rituximab combined with pirarubicin chemotherapy regimen in patients with non-Hodgkin's lymphoma and its effect on relative markers levels

作　　者：杨环 杨义荣 胡灯明 张峰 李何 夏梅花 冯绪 刘霞 王红芳 郭涛 黄石珍 Yang Huan;Yang Yirong;Hu Dengming;Zhang Feng;Li He;Xia Meihua;Feng Xu;Liu Xia;Wang Hongfang;Guo Tao;Huang Shizhen(Kunming First People's Hospital Ganmei International Hospital,Yunnan Kunming 650224,China;Kunming Children's Hospital,Yunnan Kunming 650228,China;Yunnan Provincial Hospital for Infectious Diseases,Yunnan Kunming 650300,China)

机构地区：[1]昆明市第一人民医院甘美国际医院,云南昆明650224 [2]昆明市儿童医院,云南昆明650228 [3]云南省传染病专科医院,云南昆明650300

出　　处：《现代肿瘤医学》2020年第15期2705-2709,共5页Journal of Modern Oncology

摘　　要：目的:探讨美罗华联合含吡柔比星(THP)化疗方案对非霍奇金淋巴瘤(NHL)的有效性和安全性及对肿瘤标志物水平的影响。方法:选取2010年1月-2012年12月于我院就诊的100例NHL患者为研究对象,以随机数字表法分为治疗组(50例)和对照组(50例)。对照组予以含THP化疗方案治疗,治疗组在对照组的基础上予以美罗华治疗,21 d为1个周期,两组均治疗6个周期。比较两组的临床疗效、无进展生存期(PFS)和总生存期(OS)、治疗前后的血管内皮生长因子(VEGF)、乳酸脱氢酶(LDH)及β2-微球蛋白(β2-MG)等肿瘤标志物水平、生活质量(EORTC QLQ-C30)评分、不良反应。结果:治疗组的有效率为84.00%,显著高于对照组的66.00%(P<0.05);治疗组的中位PFS为6.6个月,对照组为3.5个月(2~8个月),两组比较差异显著(P<0.05),治疗组中位OS为1.5年,对照组为0.9年,两组比较差异显著(P<0.05);治疗组的VEGF、LDH、β2-MG水平均显著低于对照组(P<0.05);治疗组的各项生活质量评分显著高于对照组(P<0.05);两组不良反应比较差异无显著性(P>0.05)。结论:美罗华联合含THP化疗方案治疗NHL抗肿瘤效果显著,明显延长生存时间,并提高患者生活质量。Objective:To explore the effectiveness and safety of rituximab combined with pirarubicin(THP)chemotherapy regimen for non-Hodgkin's lymphoma(NHL)and its effects on tumor markers levels.Methods:100 cases of NHL patients who were admitted to our hospital from January 2010 to December 2012 were selected for the study and were divided into treatment group(50 cases)and control group(50 cases)according to the random number table method.Control group was treated with THP chemotherapy regimen,and treatment group was treated with rituximab on the basis of control group.The two groups were treated for 6 cycles with 1 cycle of 21 d.Clinical efficacy,progression-free survival(PFS),and overall survival(OS),tumor marker levels of vascular endothelial growth factor(VEGF),lactate dehydrogenase(LDH),andβ2-microglobulin(β2-MG)before and after treatment,quality of life(EORTC QLQ-C30)score and adverse reactions were compared between the two groups.Results:The effective rate in treatment group was significantly higher than that in control group(84.00%vs 66.00%)(P<0.05).The median PFS was 6.6 months in treatment group,and was 3.5 months(2~8 months)in control group(P<0.05),and the median OS was 1.5 years in treatment group,and was 0.9 years in control group(P<0.05).The levels of VEGF,LDH andβ2-MG in treatment group were significantly lower than those in control group(P<0.05),and the scores of items of quality of life in treatment group were significantly higher than those in control group(P<0.05).There were no significant differences in adverse reactions between the two groups(P>0.05).Conclusion:Rituximab combined with THP chemotherapy regimen for NHL has significant anti-tumor effects,significantly prolong survival time and improve patients'quality of life.

关 键 词：美罗华 吡柔比星 非霍奇金淋巴瘤 血管内皮生长因子 乳酸脱氢酶 

分 类 号：R733.4[医药卫生—肿瘤]